At a glance
ClinicalIndex Comparison RecordN/ACompleted· 195 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real-World Treatment Patterns and Outcomes in Postmenopausal, Hormone-Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative, Metastatic Breast Cancer Patients Treated With Palbociclib Plus an Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
In Brief
An observational study for Breast Cancer. Completed, enrolled 195 participants across 1 site.
Detailed Summary
This is a retrospective, observational study that will document treatment patterns and clinical outcomes of postmenopausal patients diagnosed with HR+/HER2- mBC who received Palbociclib plus Letrozole as initial endocrine-based therapy in US community oncology network settings.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
Primary CompletionJun 2019
First PostedJul 2020
TodayJul 2026
First PostedJul 8, 2020
Enrollment StartJan 4, 2019
Primary CompletionJun 24, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.0 years ago